Novavax to Participate in Upcoming Conferences
October 05 2020 - 9:00AM
Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company
developing next-generation vaccines for serious infectious
diseases, today announced that it will participate in four upcoming
investor and industry conferences. Novavax’ COVID-19 vaccine
candidate, NVX-CoV2373, is expected to be discussed in each
conference.
Maryland Life Sciences Bio Innovation
Conference |
Date: |
Monday, October 5, 2020 |
Time: |
10:25 -11:25 a.m. ET |
Panel title: |
Discussion on Pandemic & Risk Mitigation: A Focus on
Preparation & ResiliencyThree Maryland biotech leaders discuss
how to prepare for the unforeseen and what is needed to pivot for
the future. |
Panelist: |
John Trizzino, Executive Vice President, Chief Business Officer and
Chief Financial Officer |
To attend: |
Click here to register. |
|
Guggenheim First Annual Vaccines and
Infectious Diseases Conference |
Date: |
Monday, October 5, 2020 |
Time: |
4:15 - 4:45 p.m. ET |
Participation: |
Fireside chat and investor meetings |
Novavax participants: |
Gregory M. Glenn, M.D., President of Research and Development, and
John J. Trizzino, Executive Vice President, Chief Business Officer
and Chief Financial Officer |
Webcast: |
A replay of the session will be available within 48 hours through
the events page of the Company’s website at ir.novavax.com for 90
days following the event. |
|
Goldman Sachs Virtual Event:
Inoculating the Recovery
--A Discussion on COVID-19 Vaccines,
Treatments, Testing of the Economy |
Date: |
Thursday, October 8, 2020 |
Time: |
12:00 - 12:55 p.m. ET |
Panel title: |
Vaccines – Approaching the Light at the End of the Tunnel |
Panelist: |
Gregory M. Glenn, M.D. President of Research and DevelopmentThis
event is open to Goldman Sachs clients. |
|
BioHealth Capital Region Forum |
Date: |
Monday, October 19, 2020 |
Time: |
12:45 - 1:30 p.m. ET |
Panel title: |
Strengths of our Region: Combatting Infectious Disease |
Panelist: |
Vivek, Shinde, M.D., Vice President of Clinical Development |
To attend: |
Click here to register. |
|
|
About NVX-CoV2373
NVX-CoV2373 is a vaccine candidate engineered
from the genetic sequence of SARS-CoV-2, the virus that causes
COVID-19 disease. NVX-CoV2373 was created using Novavax’
recombinant nanoparticle technology to generate antigen derived
from the coronavirus spike (S) protein and contains Novavax’
patented saponin-based Matrix-M™ adjuvant to enhance the immune
response and stimulate high levels of neutralizing antibodies.
NVX-CoV2373 contains purified protein antigen and cannot replicate,
nor can it cause COVID-19. In preclinical trials, NVX-CoV2373
demonstrated indication of antibodies that block binding of spike
protein to receptors targeted by the virus, a critical aspect for
effective vaccine protection. In the Phase 1 portion of its Phase
1/2 clinical trial, NVX-CoV2373 was generally well-tolerated and
elicited robust antibody responses numerically superior to that
seen in human convalescent sera. NVX-CoV2373 is also being
evaluated in a Phase 3 trial in the UK and two ongoing Phase 2
studies that began in August; a Phase 2b trial in South Africa, and
a Phase 1/2 continuation in the U.S. and Australia. Novavax has
secured $2 billion in funding for its global coronavirus vaccine
program, including up to $388 million in funding from the Coalition
for Epidemic Preparedness Innovations (CEPI).
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage
biotechnology company that promotes improved health globally
through the discovery, development, and commercialization of
innovative vaccines to prevent serious infectious diseases. Novavax
is undergoing clinical trials for NVX-CoV2373, its vaccine
candidate against SARS-CoV-2, the virus that causes COVID-19.
NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all
primary objectives in its pivotal Phase 3 clinical trial in older
adults. Both vaccine candidates incorporate Novavax’ proprietary
saponin-based Matrix-M™ adjuvant in order to enhance the immune
response and stimulate high levels of neutralizing antibodies.
Novavax is a leading innovator of recombinant vaccines; its
proprietary recombinant technology platform combines the power and
speed of genetic engineering to efficiently produce highly
immunogenic nanoparticles in order to address urgent global health
needs. For more information, visit www.novavax.com and connect with
us on Twitter and LinkedIn.
Contacts:
InvestorsSilvia Taylor and Erika
Trahanir@novavax.com240-268-2022
Media Brandzone/KOGS CommunicationEdna Kaplan kaplan@kogspr.com
617-974-8659
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024